eSURFACE 1 and reSURFACE 2: Biological therapy improves psoriasis and CVD

As a fact, cardiovascular diseases (CVD) are highly prevalent in patients with psoriasis, and hence Professor Nehal Mehta and his team have been using this as a model to study inflammatory atherogenesis. In this MEDtalk, he presents very interesting results from the reSURFACE 1 and 2 regarding the association between psoriasis and CVD and how both conditions improve following biological therapy with tildrakizumab.